scholarly journals Mitochondrial dysfunction driven by the LRRK2-mediated pathway is associated with loss of Purkinje cells and motor coordination deficits in diabetic rat model

2014 ◽  
Vol 5 (5) ◽  
pp. e1217-e1217 ◽  
Author(s):  
S Yang ◽  
C Xia ◽  
S Li ◽  
L Du ◽  
L Zhang ◽  
...  
2019 ◽  
Vol 19 (5) ◽  
pp. 622-631 ◽  
Author(s):  
Ya Liu ◽  
Jian Kang ◽  
Hong Gao ◽  
Xiyu Zhang ◽  
Jun Chao ◽  
...  

Background: Type 2 Diabetes Mellitus (T2DM) is a world-wide metabolic disease with no cure from drugs and treatment. In China, The Traditional Chinese Medicine (TCM) herbal formulations have been used to treat T2DM for centuries. Methods: In this study, we proposed a formula called ShenQi Compound (SQC), which has been used in clinical therapeutics in China for several years. We evaluated the effect of SQC in a spontaneous diabetic rat model (GK rats) by detecting a series of blood indicators and performing histological observations. Meanwhile, the gene microarray and RT-qPCR experiments were used to explore the molecular mechanism of SQC treatment. In addition, western medicine, sitagliptin was employed as a comparison. Results: The results indicated that SQC and sitagliptin could effectively improve the serum lipid (blood Total Cholesterol (TC) and blood Triglycerides (TG)), hormone levels (serum insulin (INS), Glucagon (GC) and Glucagon-Like Peptide-1 (GLP-1)), alleviated the inflammatory response (hypersensitive C-Reactive Protein (hsCRP)), blood glucose fluctuation (Mean Blood Glucose (MBG), standard deviation of blood glucose (SDBG) and Largest Amplitude of plasma Glucose Excursions (LAGE)), pancreatic tissue damage and vascular injury for T2DM. Compared with sitagliptin, SQC achieved a better effect on blood glucose fluctuation (p<0.01). Meanwhile, the gene microarray and RT-qPCR experiments indicated that SQC and sitagliptin may improve the T2DM through affecting the biological functions related to apoptosis and circadian rhythm. Moreover, SQC might be able to influence the mTOR signaling pathway by regulating Pik3r1, Ddit4 expression. Conclusion: All these results indicate that SQC is an effective therapeutic drug on T2DM. Notably, SQC presents an obvious blood glucose fluctuation-preventing ability, which might be derived from the regulation of the mTOR signaling pathway.


2015 ◽  
Vol 10 (2) ◽  
pp. 778-786 ◽  
Author(s):  
DE-HAI YIN ◽  
XIAO-CHUN LIANG ◽  
LI ZHAO ◽  
HONG ZHANG ◽  
QING SUN ◽  
...  

2013 ◽  
Vol 28 (5) ◽  
pp. 725 ◽  
Author(s):  
Sun-Ouck Kim ◽  
Hyun-Suk Lee ◽  
Kyuyoun Ahn ◽  
Kwangsung Park

2019 ◽  
Vol 16 (1) ◽  
pp. e1800365
Author(s):  
Regiane C. Duarte ◽  
Silvia H. Taleb-Contini ◽  
Paulo S. Pereira ◽  
Camila F. Oliveira ◽  
Carlos Eduardo S. Miranda ◽  
...  

2012 ◽  
Vol 265 (2) ◽  
pp. 209-220 ◽  
Author(s):  
Zivanit Ergaz ◽  
Dana Shoshani-Dror ◽  
Claire Guillemin ◽  
Meytal Neeman-azulay ◽  
Liza Fudim ◽  
...  

2015 ◽  
Vol 26 (8) ◽  
pp. 1768-1776 ◽  
Author(s):  
Yanmin Wang ◽  
Xiang Zhang ◽  
Mingwei Zhong ◽  
Teng Liu ◽  
Guangyong Zhang ◽  
...  

2018 ◽  
Vol 4 (2) ◽  
pp. 181-188 ◽  
Author(s):  
Medhat Ahmed El-Zainy ◽  
Ahmed Mahmoud Halawa ◽  
Fatma Adel Saad

2020 ◽  
Vol 66 (Supplement) ◽  
pp. S36-S40
Author(s):  
Deni ELNOVRIZA ◽  
Hadi RIYADI ◽  
Rimbawan RIMBAWAN ◽  
Evy DAMAYANTHI ◽  
Adi WINARTO

Sign in / Sign up

Export Citation Format

Share Document